$ABT

$ABBV and $BMY deliver above-average dividend yields and growth, standing out as rare healthcare sector exceptions for patient income investors navigating patent cliffs through innovation.

Abbott Laboratories and Intuitive Surgical offer defensive healthcare positioning through diversification, dividend stability, and recurring revenue models amid market uncertainty.

$ABT down 22% after disappointing earnings, but strong medical devices and $21B Exact Sciences deal offer recovery potential for income seekers.

Global IV solutions market projected to surge from $13.35B in 2025 to $29.47B by 2035, driven by rising chronic disease prevalence and critical care demand.

Dividend Kings Johnson & Johnson and AbbVie offer 50+ years of consecutive dividend growth with resilient pipelines successfully offsetting patent expirations.

Global personalized nutrition market projected to grow from $15.79B in 2025 to $30.94B by 2030 at 14.4% CAGR, with Asia Pacific driving expansion.

Global molecular diagnostics market projected to reach $33.51B by 2031 at 10.43% CAGR, driven by precision medicine adoption and genomic testing advances.

Global respiratory testing market projected to reach $9.32B by 2032, growing 6.50% annually from $5.99B in 2025, driven by molecular diagnostics and telemedicine innovations.

Global personalized nutrition market projected to reach $60.92 billion by 2035, growing 15% annually from $15.80 billion in 2025, driven by preventive healthcare awareness.

Global antibiotics market to grow from USD 55.60B in 2025 to USD 70.64B by 2031 at 4.07% CAGR, driven by antimicrobial resistance and innovation.

VivaVision Biotech rushes Hong Kong IPO as cash reserves dwindle to $5.2 million against $6.3 million quarterly burn rate. Two late-stage eye disease candidates drive investor appeal.

Precision medicine market expected to double to $237.28B by 2031, driven by AI advances and biomarker development at 13.58% annual growth.

Abbott maintains 54-year dividend streak with 10% EPS growth projected for 2026, despite near-term diagnostic headwinds and manufacturing challenges offsetting strategic acquisitions and FDA approvals.

Global digestive health supplements market expected to double to $25.83 billion by 2035, driven by rising GI disorders and preventive healthcare trends, though regulatory challenges persist.

Neuromodulation device market expected to double to $16.1 billion by 2032, driven by rising neurological diseases, technological advances, and regulatory support.

Abbott extends Dividend Aristocrat status with 409th consecutive quarterly payout, maintaining 54 years of dividend increases and demonstrating sustained shareholder value creation.